Skip to main content

Month: March 2020

MediPharm Labs Reports Fourth Quarter and Full Year 2019 Results

• 2019 Revenue $129 Million, Adjusted EBITDA1 $25 Million• Q4 2019 Revenue $32 Million, Adjusted EBITDA1 $3 Million• Year-end Cash and Equivalents of $39 millionBARRIE, Ontario, March 30, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products today announced its financial results for the three and twelve months ended December 31, 2019 and reaffirmed its strategic priority to build a multi-jurisdictional, GMP-certified pharmaceutical-grade platform to serve the world’s most attractive emerging cannabis medical markets.“2019 was a transformational year for MediPharm Labs. We were one of only a very few cannabis companies to successfully execute...

Continue reading

AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook

Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110 million in upfront and development milestone payments and a USD 50 million equity note in 2019 as a result of the Morphomer™ Tau Lilly partnershipAdded new potential CHF 60 million Phase 2 initiation milestone and achieved CHF 10 million milestone in Q1 2020 in Lilly partnershipFive clinical milestones expected in 2020 including the first Phase 2 readout of an anti-Tau antibody in Alzheimer’s disease (AD)Initiated three clinical trials targeting Tau and a substudy within the ongoing Phase 2 Alzheimer’s Prevention Initiative trialLAUSANNE, Switzerland, March 30, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical...

Continue reading

Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

DSG3-CAART IND clearance received in October 2019 and Orphan Drug Designation granted by the FDA for the treatment of pemphigus vulgaris (PV) in January 2020; anticipated delay in reporting the acute safety data from the first cohort of the DesCAARTesTMtrial due to the COVID-19 pandemicIND-enabling studies for MuSK-CAART, targeting the MuSK form of myasthenia gravis, to be initiated in 2020Ended 2019 with approximately $136 million in cash and cash equivalents; including net proceeds from initial public offering of approximately $71 million, sufficient to fund operations through at least the third quarter of 2022PHILADELPHIA, March 30, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated...

Continue reading

Apergy Announces Business and Merger Update Conference Call

THE WOODLANDS, Texas, March 30, 2020 (GLOBE NEWSWIRE) — Apergy Corporation (“Apergy”) (NYSE: APY) announced today that Soma Somasundaram, President and Chief Executive Officer, will host a business update call facilitated by David Anderson of Barclays on Tuesday, March 31, 2020 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). Deric Bryant, Executive Vice President of Ecolab Inc. and President of ChampionX, will join as an invited guest to discuss the pending merger between Apergy and ChampionX.The call will be available by live webcast on Apergy’s website at www.apergy.com or by dialing in as follows:Please register for the webcast or dial into the call approximately 15 minutes prior to the scheduled start time.A replay of the conference call will be available for approximately 30 days on Apergy’s website or by dialing 1-888-843-7419...

Continue reading

Black Hills Corp. Announces Upcoming Investor Meetings and Provides Business Update Related to COVID-19 Pandemic Impacts

RAPID CITY, S.D., March 30, 2020 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced that members of its senior management team will visit with equity investors March 30 and March 31 during the virtually- hosted Mizuho Energy Summit 2020. The materials produced for these meetings will be available on the Black Hills Corp. website at www.blackhillscorp.com under the “Investor Relations” section prior to the meetings. In preparation for the equity investor meetings, Black Hills is providing a business update regarding its response to the COVID-19 pandemic and related impacts on the company’s business.The company is continuing to execute its business continuity plan and has implemented a comprehensive set of actions for the health and safety of its customers, employees, business partners and the communities it serves....

Continue reading

Applied Optoelectronics Announces Narrow Linewidth Laser for automotive LIDAR

SUGAR LAND, Texas, March 30, 2020 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (Nasdaq: AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced the release of a high power and narrow linewidth laser specifically designed for Light Detection and Ranging (LIDAR) applications, particularly for automotive use.Current automotive LIDAR systems are based on near infrared lasers, however these lasers are not eye safe and therefore are limited in terms of emitted power.  This power limitation, in turn, restricts the effective sensing range of the LIDAR system.  AOI’s laser operates at longer wavelengths near 1550-nm where eye-safe emission limits are much higher and therefore detection distances are longer, making them...

Continue reading

Bavarian Nordic Updates its Financial Calendar for 2020

COPENHAGEN, Denmark, March 30, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes a revised financial calendar for 2020 due to postponement of the annual general meeting, which was scheduled, but not yet convened, for April 21, 2020. The dates for announcement of the financial reports for the remainder of 2020 remain unchanged.In light of the current COVID-19 situation, and the Danish Government’s decision to ban public gatherings of more than 10 people, Bavarian Nordic does not find it appropriate to conduct the annual general meeting under these conditions. Moreover, as the Company’s Articles of Association do not allow for conducting the general meeting electronically, the Board of Directors has decided to postpone the general meeting.The postponement is being made in accordance with the executive order no. 223 of March...

Continue reading

Bavarian Nordic opdaterer finanskalenderen for 2020

KØBENHAVN, Danmark, 30. marts 2020 – Bavarian Nordic A/S (OMX: BAVA) offentliggør i dag en opdateret finanskalender for 2020, som følge af udskydelse af den ordinære generalforsamling, der endnu ikke har været indkaldt, men var planlagt til afholdelse den 21. april 2020. Datoerne for de finansielle regnskaber for resten af 2020 forbliver uændrede.I lyset af den nuværende situation omkring COVID-19 samt den danske regerings beslutning om at forbyde forsamlinger med flere end 10 personer, finder Bavarian Nordic det ikke passende at gennemføre generalforsamlingen under disse forhold. Da selskabets vedtægter endvidere ikke muliggør elektronisk afholdelse af generalforsamlingen, har bestyrelsen besluttet at udskyde denne.Udskydelsen sker i overensstemmelse med bekendtgørelse nr. 223 af 17. marts 2020 fra Sundheds- og Ældreministeriet, i henhold...

Continue reading

Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program

PRESS RELEASEErgomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial ProgramGuildford, UK – 30 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces that it will provide drug safety services through its specialist pharmacovigilance provider, PrimeVigilance, for an ongoing US clinical trial to assess the effect of a rheumatoid arthritis treatment on patients with severe COVID-19 infection.Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “COVID-19 represents a severe and pressing challenge for all involved in the development of new medicines and we are proud to be expanding our involvement in the field by bringing our expertise in drug safety and...

Continue reading

European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks

RESEARCH TRIANGLE PARK, N.C., March 30, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) submission for approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.With this validation, the EMA has begun their formal review of the MAA under the centralized procedure for all member states of the European Union, and Norway, Iceland and Liechtenstein.An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected within approximately 12 months.“Berotralstat would represent the first targeted oral therapy approved for HAE prophylaxis in Europe and would deliver a major advance in therapy to HAE patients,” said Jon Stonehouse, chief...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.